“…Excess TNF is centrally involved in the pathophysiology of chronic brain dysfunction in multiple disease states: (a) cerebral malaria; (b) TBI; (c) stroke; (d) Alzheimer’s disease; (e) frontotemporal dementia; (f) post-surgery; (g) hepatic encephalopathy
Rationale: Etanercept reduces cognitive impairment in disorders associated with excess TNFClark 1989, 1991 [51, 181] Goodman 1990 [52] Perry 2001 [53] Tarkowski 2003 [223] Sjogren 2004 [54] Tweedie 2007 [55] Kaushal 2008 [86] John 2008 [56] Clark 2010, 2012 [32, 33] Chio 2010 [45] Terrando 2010 [57] Frankola 2011 [59] Butterworth 2011 [58] Clark 2012 [34] Chastre 2012 [213] Cheong 2013 [60] Chio 2013 [61] Miller 2013 [62] | Etanercept reduces TNF-mediated cognitive impairment in Alzheimer’s disease, other dementias, stroke, TBI, rheumatoid arthritis, sarcoidosis, hepatic encephalopathy, post status epilepticus | Tobinick 2006–2012 [10, 35, 68, 69, 146, 216, 218, 219]; Griffin 2008 [217] Shi (infliximab) 2011, 2011 [195, 196] Tobinick 2008 [204, 219] Tobinick 2011–12 [4, 5] Chio 2010 [45] Tobinick 2012 [5] Chen 2010 [206] Efferich 2010 [205] Bassi 2010 [207] Butterworth 2013 [67] Tobinick 2014 [11] |
4. Stroke and TBI cause chronic intracerebral glial activation and neuroinflammation
Rationale: Etanercept reduces glial activation and pathologic TNF concentration | Dubois 1988 [131] Myers 1991 [132] Pappata 2000 [133] Gentleman 2004 [134] Gerhard 2005 [135] Price 2006 [136] Kaushal 2008 [86] Folkersma 2011 [137] Ramlackhansingh 2011 [138] Johnson 2013 [139] | Etanercept inhibits glial activation and neuroinflammation | Marchand 2009 [64]
|
…”